ASCL.F Stock Overview
A biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ascletis Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.16 |
| 52 Week High | HK$0.27 |
| 52 Week Low | HK$0.14 |
| Beta | 0.69 |
| 11 Month Change | -9.79% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | 3,382.22% |
| 5 Year Change | n/a |
| Change since IPO | -73.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| ASCL.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.4% | -1.9% |
| 1Y | n/a | 20.2% | 30.4% |
Return vs Industry: Insufficient data to determine how ASCL.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ASCL.F performed against the US Market.
Price Volatility
| ASCL.F volatility | |
|---|---|
| ASCL.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ASCL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ASCL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 219 | Jinzi Jason Wu | www.ascletis.com |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.
Ascletis Pharma Inc. Fundamentals Summary
| ASCL.F fundamental statistics | |
|---|---|
| Market cap | US$177.44m |
| Earnings (TTM) | -US$36.30m |
| Revenue (TTM) | US$1.42m |
125.2x
P/S Ratio-4.9x
P/E RatioIs ASCL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASCL.F income statement (TTM) | |
|---|---|
| Revenue | CN¥10.09m |
| Cost of Revenue | CN¥22.72m |
| Gross Profit | -CN¥12.63m |
| Other Expenses | CN¥245.84m |
| Earnings | -CN¥258.47m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | -125.17% |
| Net Profit Margin | -2,561.68% |
| Debt/Equity Ratio | 0% |
How did ASCL.F perform over the long term?
See historical performance and comparison